<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346696</url>
  </required_header>
  <id_info>
    <org_study_id>CHN-0005</org_study_id>
    <nct_id>NCT01346696</nct_id>
  </id_info>
  <brief_title>Study on OsseoSpeed™ TX Short Implants in a Chinese Population</brief_title>
  <official_title>An Open, Prospective, Multi-center Study Assessing the OsseoSpeed™ TX Length 6 mm in in the Posterior Maxilla and Mandible. A 3-years Follow-up Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dentsply Sirona Implants</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dentsply Sirona Implants</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the clinical efficacy of OsseoSpeed™ TX 6 mm
      implants in a Chinese population by evaluation of marginal bone level alteration, implant
      stability and implant survival in the posterior mandible and maxilla up to 3 years after
      loading. The hypothesis is that one stage surgery using 6 mm OsseoSpeed™ TX implant in the
      posterior region is safe and predictable.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marginal Bone Level Alteration</measure>
    <time_frame>Evaluated from implant installation to 12 months after implant loading</time_frame>
    <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant, and expressed in millimeters. Marginal Bone Level change calculated from values obtained at delivery of permanent restoration i.e. loading of implants (baseline) compared to the values obtained at the follow-up visit 12 months after loading.
Positive value = bone gain, Negative values = bone loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Marginal Bone Level Alteration After 36 Months</measure>
    <time_frame>Evaluated from implant loading to 36 months after implant loading.</time_frame>
    <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant, and expressed in millimeters. Marginal Bone Level change calculated from values obtained at delivery of permanent restoration i.e. loading of implants (baseline) compared to the values obtained at the follow-up visit 36 months after loading.
Positive value = bone gain, Negative values = bone loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Survival</measure>
    <time_frame>Evaluated from implant installation to 36 months after implant loading.</time_frame>
    <description>Implant survival rate evaluated clinically and radiographically.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implant Stability</measure>
    <time_frame>Evaluated 36 months after implant loading.</time_frame>
    <description>Implant stability evaluated clinically/manually (recorded as stable yes/no).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Condition of the Periimplant Mucosa (PPD).</measure>
    <time_frame>Evaluated from implant loading to 36 months after implant loading.</time_frame>
    <description>Condition of the periimplant mucosa measured by assessment of probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 36 month follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).
Negative value = increased pocket depth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Condition of the Periimplant Mucosa (BoP).</measure>
    <time_frame>Evaluated from implant loading to 36 months after implant loading.</time_frame>
    <description>Condition of the periimplant mucosa will be measured by assessment of bleeding on probing (BoP).
Presented as % of the implants that show presence of bleeding at time of the 36 months follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plaque</measure>
    <time_frame>Evaluated 36 months after implant loading.</time_frame>
    <description>Occurence of plaque around the study implant. Presented as proportion of implants that showed presence of plaque at the 36 months follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crown-to-implant Ratio</measure>
    <time_frame>12 months after implant loading</time_frame>
    <description>Crown height measured radiographically from the implant-abutment interface to the most coronal point on the prosthesis. The crown-to-implant ratio calculated from radiographs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Partially Edentulous Jaw</condition>
  <arm_group>
    <arm_group_label>OsseoSpeed™ TX implants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)</intervention_name>
    <arm_group_label>OsseoSpeed™ TX implants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Provision of informed consent

          2. Female and male aged 20-75 years at enrolment

          3. In need for 2-3 implants in either side of the posterior mandible or maxilla (premolar
             and molar region)

          4. History of edentulism in the study area of at least four months

          5. Neighboring tooth/teeth to the planned bridge/crowns must have natural root(s)

          6. Presence of natural teeth, partial prosthesis and/or implants in the opposite jaw in
             contact with the planned bridge/crowns

          7. Deemed by the investigator to be suitable for implants of 6 mm length and to have a
             bone height of at least 6 mm and a bone width of minimum 6 mm

          8. Deemed by the investigator as likely to present an initially stable implant situation

        Exclusion criteria:

          1. Unlikely to be able to comply with study procedures, as judged by the investigator

          2. Earlier graft procedures in the study area

          3. Uncontrolled pathologic processes in the oral cavity

          4. Known or suspected current malignancy

          5. History of radiation therapy in the head and neck region

          6. History of chemotherapy within 5 years prior to surgery

          7. Systemic or local disease or condition that could compromise post-operative healing
             and/or osseointegration

          8. Uncontrolled diabetes mellitus

          9. Corticosteroids or any other medication that could influence post-operative healing
             and/or osseointegration

         10. Smoking more than 10 cigarettes/day

         11. Present alcohol and/or drug abuse

         12. Involvement in the planning and conduct of the study (applies to both Astra Tech staff
             and staff at the study site)

         13. Previous enrolment in the present study

         14. Simultaneous participation in another clinical study, or participation in a clinical
             study during the last 6 months

         15. Subjects that are unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huan Xin Meng, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Periodontology, School of Stomatology, Beijing University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Periodontology, School of Stomatology, Peking University</name>
      <address>
        <city>Beijing</city>
        <zip>100081</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Implantology, School of Stomatology, Peking University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Second Dental and Periodontal Center, School of Stomatology, Peking University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Han J, Zhang X, Tang Z, Zhang L, Shi D, Meng H. A prospective, multicenter study assessing the DENTSPLY Implants, OsseoSpeed(™) TX, length 6 mm in the posterior maxilla and mandible: a 1-year follow-up study. Clin Oral Implants Res. 2016 Apr;27(4):452-7. doi: 10.1111/clr.12587. Epub 2015 Apr 9.</citation>
    <PMID>25855871</PMID>
  </results_reference>
  <results_reference>
    <citation>Han J, Tang Z, Zhang X, Meng H. A prospective, multi-center study assessing early loading with short implants in posterior regions. A 3-year post-loading follow-up study. Clin Implant Dent Relat Res. 2018 Feb;20(1):34-42. doi: 10.1111/cid.12568. Epub 2017 Dec 8.</citation>
    <PMID>29218810</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <results_first_submitted>February 11, 2019</results_first_submitted>
  <results_first_submitted_qc>February 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2019</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Jaw, Edentulous</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OsseoSpeed™ TX Implants</title>
          <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OsseoSpeed™ TX Implants</title>
          <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>Implants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Marginal Bone Level Alteration</title>
        <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant, and expressed in millimeters. Marginal Bone Level change calculated from values obtained at delivery of permanent restoration i.e. loading of implants (baseline) compared to the values obtained at the follow-up visit 12 months after loading.
Positive value = bone gain, Negative values = bone loss.</description>
        <time_frame>Evaluated from implant installation to 12 months after implant loading</time_frame>
        <population>45 subjects (90 implants) completed the 12-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
Six of the collected radiographs were not possible to evaluate, giving an overall number of 35 subjects (69 implants) as basis for the 12 months analysis of MBL change.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX Implants</title>
            <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Marginal Bone Level Alteration</title>
          <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant, and expressed in millimeters. Marginal Bone Level change calculated from values obtained at delivery of permanent restoration i.e. loading of implants (baseline) compared to the values obtained at the follow-up visit 12 months after loading.
Positive value = bone gain, Negative values = bone loss.</description>
          <population>45 subjects (90 implants) completed the 12-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
Six of the collected radiographs were not possible to evaluate, giving an overall number of 35 subjects (69 implants) as basis for the 12 months analysis of MBL change.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Marginal Bone Level Alteration After 36 Months</title>
        <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant, and expressed in millimeters. Marginal Bone Level change calculated from values obtained at delivery of permanent restoration i.e. loading of implants (baseline) compared to the values obtained at the follow-up visit 36 months after loading.
Positive value = bone gain, Negative values = bone loss.</description>
        <time_frame>Evaluated from implant loading to 36 months after implant loading.</time_frame>
        <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
Four of the collected radiographs were not possible to evaluate, giving an overall number of 35 subjects (71 implants) as basis for the 36 months analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX Implants</title>
            <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Marginal Bone Level Alteration After 36 Months</title>
          <description>Marginal Bone Level determined from radiographs and expressed as the difference from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant, and expressed in millimeters. Marginal Bone Level change calculated from values obtained at delivery of permanent restoration i.e. loading of implants (baseline) compared to the values obtained at the follow-up visit 36 months after loading.
Positive value = bone gain, Negative values = bone loss.</description>
          <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
Four of the collected radiographs were not possible to evaluate, giving an overall number of 35 subjects (71 implants) as basis for the 36 months analysis.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Survival</title>
        <description>Implant survival rate evaluated clinically and radiographically.</description>
        <time_frame>Evaluated from implant installation to 36 months after implant loading.</time_frame>
        <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX Implants</title>
            <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Survival</title>
          <description>Implant survival rate evaluated clinically and radiographically.</description>
          <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implant Stability</title>
        <description>Implant stability evaluated clinically/manually (recorded as stable yes/no).</description>
        <time_frame>Evaluated 36 months after implant loading.</time_frame>
        <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX Implants</title>
            <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Implant Stability</title>
          <description>Implant stability evaluated clinically/manually (recorded as stable yes/no).</description>
          <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Condition of the Periimplant Mucosa (PPD).</title>
        <description>Condition of the periimplant mucosa measured by assessment of probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 36 month follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).
Negative value = increased pocket depth</description>
        <time_frame>Evaluated from implant loading to 36 months after implant loading.</time_frame>
        <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
Baseline and/or follow-up measurements not available for 3 implants, giving an overall number of 36 subjects (72 implants) as basis for the 36 months analysis of PPD change.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX Implants</title>
            <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Condition of the Periimplant Mucosa (PPD).</title>
          <description>Condition of the periimplant mucosa measured by assessment of probing pocket depth (PPD).
Change in pocket depth expressed in millimeters at the 36 month follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).
Negative value = increased pocket depth</description>
          <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
Baseline and/or follow-up measurements not available for 3 implants, giving an overall number of 36 subjects (72 implants) as basis for the 36 months analysis of PPD change.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Condition of the Periimplant Mucosa (BoP).</title>
        <description>Condition of the periimplant mucosa will be measured by assessment of bleeding on probing (BoP).
Presented as % of the implants that show presence of bleeding at time of the 36 months follow-up.</description>
        <time_frame>Evaluated from implant loading to 36 months after implant loading.</time_frame>
        <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
The BoP measurement was not completed for one implant, giving an overall number of 36 subjects (74 implants) as basis for the 36 months analysis of BoP.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX Implants</title>
            <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Condition of the Periimplant Mucosa (BoP).</title>
          <description>Condition of the periimplant mucosa will be measured by assessment of bleeding on probing (BoP).
Presented as % of the implants that show presence of bleeding at time of the 36 months follow-up.</description>
          <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
The BoP measurement was not completed for one implant, giving an overall number of 36 subjects (74 implants) as basis for the 36 months analysis of BoP.</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plaque</title>
        <description>Occurence of plaque around the study implant. Presented as proportion of implants that showed presence of plaque at the 36 months follow-up visit.</description>
        <time_frame>Evaluated 36 months after implant loading.</time_frame>
        <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
Plaque measurement was not completed for one implant, giving an overall number of 36 subjects (74 implants) as basis for the 36 months analysis of Plaque.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX Implants</title>
            <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Plaque</title>
          <description>Occurence of plaque around the study implant. Presented as proportion of implants that showed presence of plaque at the 36 months follow-up visit.</description>
          <population>44 subjects (90 implants) completed the 36-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
Plaque measurement was not completed for one implant, giving an overall number of 36 subjects (74 implants) as basis for the 36 months analysis of Plaque.</population>
          <units>Implants</units>
          <param>Count of Units</param>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Crown-to-implant Ratio</title>
        <description>Crown height measured radiographically from the implant-abutment interface to the most coronal point on the prosthesis. The crown-to-implant ratio calculated from radiographs</description>
        <time_frame>12 months after implant loading</time_frame>
        <population>45 subjects (90 implants) completed the 12-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
6 of the collected radiographs were not possible to evaluate, giving an overall number of 35 subjects (68 implants) as basis for 12 months analysis of Crown-to-implant ratio.</population>
        <group_list>
          <group group_id="O1">
            <title>OsseoSpeed™ TX Implants</title>
            <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
          </group>
        </group_list>
        <measure>
          <title>Crown-to-implant Ratio</title>
          <description>Crown height measured radiographically from the implant-abutment interface to the most coronal point on the prosthesis. The crown-to-implant ratio calculated from radiographs</description>
          <population>45 subjects (90 implants) completed the 12-month follow-up visit. Protocol deviations were excluded, giving a per-protocol analysis population of 36 subjects (75 implants).
6 of the collected radiographs were not possible to evaluate, giving an overall number of 35 subjects (68 implants) as basis for 12 months analysis of Crown-to-implant ratio.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Implants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Implants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OsseoSpeed™ TX Implants</title>
          <description>OsseoSpeed TX implants; Ø 4.0 mm, length 6 mm.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic hilum cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right femoral neck fracture</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Study implant not stable - implant lost</sub_title>
                <description>4 subjects lost one of their implants due to insufficient osseointegration. Those were all lost during the healing phase, before loading of the implant.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Study implant not stable - extended healing time</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>3 subjects had implants that required extended healing time in order to achieve stability.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager Global Clinical Research</name_or_title>
      <organization>Dentsply Sirona Implants, Mölndal, SWEDEN</organization>
      <phone>0046313763500</phone>
      <email>ClinicalResearchMolndal@dentsplysirona.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

